付繩明

[摘要] 目的 改良式經(jīng)尿道雙極等離子前列腺切除（PKRP）術(shù)聯(lián)合M受體拮抗劑（托特羅定）對良性前列腺增生（BPH）患者的治療效果及對患者性功能的影響。方法 方便選取2016年1月—2018年1月該院收治的BPH患者100例，按照完全隨機法將所有患者分為PKRP術(shù)組和聯(lián)合組，各50例。PKRP術(shù)組患者采用改良式PKRP術(shù)進行治療，聯(lián)合組患者采用改良式PKRP術(shù)聯(lián)合M受體拮抗劑（托特羅定）進行治療。評價患者術(shù)后尿道功能、性功能、射精功能、治療效果及并發(fā)癥發(fā)生情況。結(jié)果 聯(lián)合治療組患者術(shù)后最大尿流量、殘余尿量、前列腺癥狀分別為（26.35±2.15）mL/s、（11.00±1.20）mL、（8.86±0.59）分均優(yōu)于改良PKRP術(shù)組（19.25±1.06）mL/s、（20.32±2.57）mL、（6.23±0.23）分（t=20.940、23.230、29.370，P=0.001、0.001、0.001）。聯(lián)合治療組患者治療有效率為96.00%（48/50）高于改良PKRP術(shù)組80.00%（40/50），并發(fā)癥發(fā)生率為4.00%（2/50）低于改良PKRP術(shù)組18.00%（9/50）（χ2=6.061、5.005，P=0.014、0.025）。結(jié)論 BPH患者應用改良式PKRP術(shù)聯(lián)合M受體拮抗劑治療可改善患者尿道功能、性功能，效果顯著，且并發(fā)癥較少，安全性較高。

[關(guān)鍵詞] 改良式經(jīng)尿道雙極等離子前列腺切除;M受體拮抗劑;托特羅定;良性前列腺增生

[中圖分類號] R5 ? ? ? ? ?[文獻標識碼] A ? ? ? ? ?[文章編號] 1674-0742（2020）07（a）-0032-03

[Abstract] Objective The effect of modified transurethral bipolar plasma prostatectomy （PKRP） combined with M receptor antagonist （tolterodine） on patients with benign prostatic hyperplasia （BPH） and its sexual function Methods 100 patients with BPH admitted to the hospital from January 2016 to January 2018 were convenient selected， and all patients were divided into PKRP surgery group and 50 patients in the combined group according to the completely random method. Patients in the PKRP group were treated with modified PKRP， and patients in the combined group were treated with modified PKRP combined with M receptor antagonist （tolterodine）. Evaluate the patients' postoperative urethral function， sexual function， ejaculation function， treatment effect and complications. Results The maximum postoperative urine flow， residual urine volume， and prostate symptoms of the combined treatment group were （26.35±2.15） mL/s，（11.00±1.20）mL，（8.86±0.59） points， which were better than the modified PKRP surgery group （19.25±1.06） mL/s， （20.32±2.57） mL， （6.23±0.23） points） （t=20.940， 23.230， 29.370，P=0.001，0.001，0.001）. The effective rate of patients in the combined treatment group was 96.00% （48/50） higher than that in the modified PKRP group 80.00% （40/50）， and the complication rate was 4.00% （2/50） lower than the modified PKRP group 18.00% （9/50） （χ2=6.061，5.005，P=0.014，0.025）. Conclusion The treatment of BPH patients with modified PKRP combined with M receptor antagonist can improve the urethral function and sexual function of patients with significant effects， fewer complications， and higher safety.

[Key words] Modified transurethral bipolar plasma prostatectomy; M receptor antagonist; Tolterodine; Benign prostatic hyperplasia